Teva Poised to Get a Big Boost in Generics - WSJ
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Israel stocks up; FTC eyes Teva-Cephalon deal - MarketWatch
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Israel stocks rise, led by Teva, ICL - MarketWatch
Teva Pharmaceuticals reports earnings on Wednesday. Here's what to expect - MarketWatch
Teva stock drops on guidance, manufacturing problems - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Israeli stocks rise; Brainsway, Ratio Oil off - MarketWatch
Latest twist in pharma love triangle as Teva pursues Mylan merger - MarketWatch
Drug stocks move higher in late trading - MarketWatch
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls - MarketWatch
Teva Pharmaceuticals - Wikipedia
Tel Aviv losing streak extends into third day - MarketWatch
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Teva Pharmaceutical Settles Opioid Suit With West Virginia - MarketWatch
Israel stocks ease; Teva loses patent ruling - MarketWatch
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls - MarketWatch
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Billionaire health-care investor Phillip Frost charged by SEC with pump-and-dump schemes - MarketWatch
Teva Pharmaceutical to pay $110 mln to settle opioid charges in W. Va. - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
